EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modeling Antibody Kinetics Post‐mRNA Booster Vaccination and Protection Durations Against SARS‐CoV‐2 Infection

Luis J Ponce, Yuqian Wang, Ananya Singh, Hoong Kai Chua iD, Marc Chen, Pei Xiang Hor, Chiew Yee Loh, Xuan Ying Poh, Suma Rao, Po Ying Chia, Sean W X Ong, Tau Hong Lee und 7 weitere

Journal of Medical Virology · 2025-08 · 97 (8)

DOI: 10.1002/jmv.70521 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 06.08.2025. Verfasst von Luis J Ponce und 18 weiteren Autor:innen. Beteiligte Einrichtung: Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. Hauptthemen laut MEDLINE: COVID-19, Antibodies, Viral, Immunization, Secondary, SARS-CoV-2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was supported in part by the Ministry of Education, Singapore, under the Academic Research Fund Tier 1 Seed Award (RLMOE100201900000001) (to KE), a….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Understanding the dynamics of SARS‐CoV‐2 antibody levels post‐booster vaccination is important to inform their durations of protection. Longitudinal antibody data was collected on the day of booster vaccination, as well as 28, 180, and 360 days after. Using nonlinear mixed effects models, we mapped the kinetics of binding IgA and IgG against wild‐type (WT) and Omicron BA.1 spike proteins. Furthermore, we analyzed the association between antibody levels and risk of SARS‐CoV‐2 vaccine breakthrough infection through survival analyzes, and predicted durations of protection against infection. We found that the antibody response waned more rapidly following the Pfizer/BioNTech BNT162b2 booster compared to the Moderna mRNA‐1273 booster. However, individuals boosted with the Pfizer vaccine exhibited a steeper rebound in antibody levels after infection. Faster postinfection antibody growth rates were observed in the elderly, females, and those with late infections. High antibody levels for WT IgG and BA.1 IgA at day 28 post‐booster were associated with reduced infection risk; hazard ratios were 0.47 (95% CI [0.22, 0.98]) and 0.36 (95% CI [0.17, 0.78]), respectively, compared to low levels. Time‐varying antibody levels showed better survival model fits. At medium COVID‐19 case incidence (621 cases per million per day), a binding BA.1 IgA response of at least 20% is needed to sustain 80% protection against infection over 155 days post‐booster. Our estimates of protection durations against SARS‐CoV‐2 infection post‐booster vaccination may help inform the ideal frequency of boosters.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Antibodies, ViralImmunization, SecondarySARS-CoV-2COVID-19 VaccinesHumansFemaleImmunoglobulin GMaleMiddle AgedBNT162 VaccineAdultAgedSpike Glycoprotein, CoronavirusImmunoglobulin A2019-nCoV Vaccine mRNA-1273Young AdultKinetics

Stichwörter der Autor:innen

COVID‐19 breakthrough infectionsCOVID‐19 vaccinesSARS‐CoV‐2immunoglobulin Aimmunoglobulin Gsurvival analysis

Substanzen

Antibodies, ViralImmunoglobulin GBNT162 VaccineCOVID-19 VaccinesSpike Glycoprotein, CoronavirusImmunoglobulin A2019-nCoV Vaccine mRNA-1273spike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
  • School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
  • A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology, and Research (A*STAR), Singapore, Singapore.
  • National Center for Infectious Diseases (NCID), Singapore, Singapore.
  • Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore.
  • National Healthcare Group, Singapore, Singapore.

ORCID-Profile: Hoong Kai Chua, Keisuke Ejima

Förderung

  • This study was supported in part by the Ministry of Education, Singapore, under the Academic Research Fund Tier 1 Seed Award (RLMOE100201900000001) (to KE), a…

Zitieren

APA

Ponce, L. J., Wang, Y., Singh, A., Chua, H. K., Chen, M., Hor, P. X., Loh, C. Y., Poh, X. Y., Rao, S., Chia, P. Y., Ong, S. W. X., Lee, T. H., Lin, R. J. H., Lim, C., Teo, J., Goh, Y. S., Ejima, K., on behalf of the NCID Study Group, & on behalf of the COVID‐19 Cohort Study Group (2025). Modeling Antibody Kinetics Post‐mRNA Booster Vaccination and Protection Durations Against SARS‐CoV‐2 Infection. Journal of Medical Virology, 97(8). https://doi.org/10.1002/jmv.70521

Vancouver

Ponce LJ, Wang Y, Singh A, Chua HK, Chen M, Hor PX, et al. Modeling Antibody Kinetics Post‐mRNA Booster Vaccination and Protection Durations Against SARS‐CoV‐2 Infection. Journal of Medical Virology. 2025;97(8). doi:10.1002/jmv.70521

BibTeX
@article{Ponce2025,
  author = {Ponce, Luis J and Wang, Yuqian and Singh, Ananya and Chua, Hoong Kai and Chen, Marc and Hor, Pei Xiang and Loh, Chiew Yee and Poh, Xuan Ying and Rao, Suma and Chia, Po Ying and Ong, Sean W X and Lee, Tau Hong and Lin, Ray J H and Lim, Clarissa and Teo, Jefanie and Goh, Yun Shan and Ejima, Keisuke and on behalf of the NCID Study Group, on behalf of the NCID Study Group and on behalf of the COVID‐19 Cohort Study Group, on behalf of the COVID‐19 Cohort Study Group},
  title = {Modeling Antibody Kinetics Post‐mRNA Booster Vaccination and Protection Durations Against SARS‐CoV‐2 Infection},
  journal = {Journal of Medical Virology},
  year = {2025},
  volume = {97},
  number = {8},
  doi = {10.1002/jmv.70521}
}
Kostenlos starten →